Compounds > iso-sulfan blue
Page last updated: 2024-09-22

iso-sulfan blue

Description

iso-sulfan blue: 2,5-disulfobenzylidene-isomer of sulfan blue; RN given refers to Na salt; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID50108
CHEMBL ID1200859
SCHEMBL ID3324345
MeSH IDM0084883

Synonyms (51)

Synonym
p-1888
68238-36-8
D04634
lymphazurin (tn)
isosulfan blue (usan)
p-4125
lymphazurin
isosulfan blue
nsc-734902
isosulfan blue [usan]
sulfanblau
patent blau v
sulphan blue 2,5-disulfophenyl isomer
sulphan blue
iso-sulfan blue
disulphin blau
(4-(alpha-(p-(diethylamino)phenyl)-2,5-disulfobenzylidene)-2,5-cyclohexadien-1-ylidene)diethylammonium hydroxide, inner salt, sodium salt
p 4125
p 1888
ethanaminium, n-(4-((4-(diethylamino)phenyl)(2,5-disulfophenyl)methylene)-2,5-cyclohexadien-1-ylidene)-n-ethyl-, hydroxide, inner salt, sodium salt
CHEMBL1200859
39n9k8s2a4 ,
hsdb 8071
nsc 734902
unii-39n9k8s2a4
AKOS015904521
(4-(.alpha.-(p-(diethylamino)phenyl)-2,5-disulfobenzylidene)-2,5-cyclohexadien-1-ylidene)diethylammonium hydroxide, inner salt, sodium salt
isosulfan blue [who-dd]
sulphan blue 2,5-disulfophenyl isomer [mi]
sodium 2-((4-(diethylamino)phenyl)(4-(diethyliminio)cyclohexa-2,5-dien-1-ylidene)methyl)benzene-1,4-disulphonate
ethanaminium, n-(4-((4-(diethylamino)phenyl)(2,5-disulfophenyl)methylene)-2,5-cyclohexadien-1-ylidene)-n-ethyl-, inner salt, sodium salt
isosulfan blue [vandf]
sodium 2-((4-(diethylamino)phenyl)(4-(diethyliminio)cyclohexa-2,5-dien-1-ylidene)methyl)benzene-1,4-disulfonate ,
isosulfan blue [orange book]
SCHEMBL3324345
NCGC00253597-01
tox21_113733
cas-68238-36-8
dtxcid6031594
dtxsid8057805 ,
FD10698
SY238240
mfcd00867653
patentblueviolet
sodium;2-[[4-(diethylamino)phenyl]-(4-diethylazaniumylidenecyclohexa-2,5-dien-1-ylidene)methyl]benzene-1,4-disulfonate
azul isosulfano
bleu isosulfan
azul de isosulfan
blu isosulfan
n-(4-((4-(diethylamino)phenyl)(2,5-disulfophenyl)methylene)-2,5-cyclohexadien-1-ylidene)-n-ethyl-ethanaminium hydroxide
2,5-disulfophenyl isomer

Protein Targets (23)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
LuciferasePhotinus pyralis (common eastern firefly)Potency12.30180.007215.758889.3584AID1224835
RAR-related orphan receptor gammaMus musculus (house mouse)Potency13.89560.006038.004119,952.5996AID1159521; AID1159523
Fumarate hydrataseHomo sapiens (human)Potency10.00000.00308.794948.0869AID1347053
GLI family zinc finger 3Homo sapiens (human)Potency4.19590.000714.592883.7951AID1259369; AID1259392
AR proteinHomo sapiens (human)Potency8.46850.000221.22318,912.5098AID1259243; AID1259247
nuclear receptor subfamily 1, group I, member 3Homo sapiens (human)Potency11.59060.001022.650876.6163AID1224838; AID1224839; AID1224893
cytochrome P450 family 3 subfamily A polypeptide 4Homo sapiens (human)Potency13.80290.01237.983543.2770AID1645841
retinoic acid nuclear receptor alpha variant 1Homo sapiens (human)Potency12.90880.003041.611522,387.1992AID1159552; AID1159553; AID1159555
estrogen-related nuclear receptor alphaHomo sapiens (human)Potency11.81930.001530.607315,848.9004AID1224841; AID1224842; AID1224848; AID1224849; AID1259401; AID1259403
estrogen nuclear receptor alphaHomo sapiens (human)Potency11.23710.000229.305416,493.5996AID1259244; AID1259248
GVesicular stomatitis virusPotency13.80290.01238.964839.8107AID1645842
cytochrome P450 2D6Homo sapiens (human)Potency15.48710.00108.379861.1304AID1645840
polyproteinZika virusPotency10.00000.00308.794948.0869AID1347053
peroxisome proliferator-activated receptor deltaHomo sapiens (human)Potency0.42160.001024.504861.6448AID743215
thyroid stimulating hormone receptorHomo sapiens (human)Potency12.95050.001628.015177.1139AID1224843; AID1224895; AID1259385; AID1259393; AID1259395
Histone H2A.xCricetulus griseus (Chinese hamster)Potency18.04210.039147.5451146.8240AID1224845; AID1224896
histone deacetylase 9 isoform 3Homo sapiens (human)Potency10.22220.037617.082361.1927AID1259364; AID1259388
Voltage-dependent calcium channel gamma-2 subunitMus musculus (house mouse)Potency10.59090.001557.789015,848.9004AID1259244
Interferon betaHomo sapiens (human)Potency13.80290.00339.158239.8107AID1645842
HLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)Potency13.80290.01238.964839.8107AID1645842
Glutamate receptor 2Rattus norvegicus (Norway rat)Potency10.59090.001551.739315,848.9004AID1259244
Inositol hexakisphosphate kinase 1Homo sapiens (human)Potency13.80290.01238.964839.8107AID1645842
cytochrome P450 2C9, partialHomo sapiens (human)Potency13.80290.01238.964839.8107AID1645842
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (45)

Processvia Protein(s)Taxonomy
cell surface receptor signaling pathway via JAK-STATInterferon betaHomo sapiens (human)
response to exogenous dsRNAInterferon betaHomo sapiens (human)
B cell activation involved in immune responseInterferon betaHomo sapiens (human)
cell surface receptor signaling pathwayInterferon betaHomo sapiens (human)
cell surface receptor signaling pathway via JAK-STATInterferon betaHomo sapiens (human)
response to virusInterferon betaHomo sapiens (human)
positive regulation of autophagyInterferon betaHomo sapiens (human)
cytokine-mediated signaling pathwayInterferon betaHomo sapiens (human)
natural killer cell activationInterferon betaHomo sapiens (human)
positive regulation of peptidyl-serine phosphorylation of STAT proteinInterferon betaHomo sapiens (human)
cellular response to interferon-betaInterferon betaHomo sapiens (human)
B cell proliferationInterferon betaHomo sapiens (human)
negative regulation of viral genome replicationInterferon betaHomo sapiens (human)
innate immune responseInterferon betaHomo sapiens (human)
positive regulation of innate immune responseInterferon betaHomo sapiens (human)
regulation of MHC class I biosynthetic processInterferon betaHomo sapiens (human)
negative regulation of T cell differentiationInterferon betaHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIInterferon betaHomo sapiens (human)
defense response to virusInterferon betaHomo sapiens (human)
type I interferon-mediated signaling pathwayInterferon betaHomo sapiens (human)
neuron cellular homeostasisInterferon betaHomo sapiens (human)
cellular response to exogenous dsRNAInterferon betaHomo sapiens (human)
cellular response to virusInterferon betaHomo sapiens (human)
negative regulation of Lewy body formationInterferon betaHomo sapiens (human)
negative regulation of T-helper 2 cell cytokine productionInterferon betaHomo sapiens (human)
positive regulation of apoptotic signaling pathwayInterferon betaHomo sapiens (human)
response to exogenous dsRNAInterferon betaHomo sapiens (human)
B cell differentiationInterferon betaHomo sapiens (human)
natural killer cell activation involved in immune responseInterferon betaHomo sapiens (human)
adaptive immune responseInterferon betaHomo sapiens (human)
T cell activation involved in immune responseInterferon betaHomo sapiens (human)
humoral immune responseInterferon betaHomo sapiens (human)
positive regulation of T cell mediated cytotoxicityHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
adaptive immune responseHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
antigen processing and presentation of endogenous peptide antigen via MHC class I via ER pathway, TAP-independentHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
regulation of T cell anergyHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
defense responseHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
immune responseHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
detection of bacteriumHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
regulation of interleukin-12 productionHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
regulation of interleukin-6 productionHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
protection from natural killer cell mediated cytotoxicityHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
innate immune responseHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
regulation of dendritic cell differentiationHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
antigen processing and presentation of endogenous peptide antigen via MHC class IbHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
inositol phosphate metabolic processInositol hexakisphosphate kinase 1Homo sapiens (human)
phosphatidylinositol phosphate biosynthetic processInositol hexakisphosphate kinase 1Homo sapiens (human)
negative regulation of cold-induced thermogenesisInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol phosphate biosynthetic processInositol hexakisphosphate kinase 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (18)

Processvia Protein(s)Taxonomy
cytokine activityInterferon betaHomo sapiens (human)
cytokine receptor bindingInterferon betaHomo sapiens (human)
type I interferon receptor bindingInterferon betaHomo sapiens (human)
protein bindingInterferon betaHomo sapiens (human)
chloramphenicol O-acetyltransferase activityInterferon betaHomo sapiens (human)
TAP bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
signaling receptor bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
protein bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
peptide antigen bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
TAP bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
protein-folding chaperone bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
inositol-1,3,4,5,6-pentakisphosphate kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol hexakisphosphate kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol heptakisphosphate kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol hexakisphosphate 5-kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
protein bindingInositol hexakisphosphate kinase 1Homo sapiens (human)
ATP bindingInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol hexakisphosphate 1-kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol hexakisphosphate 3-kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol 5-diphosphate pentakisphosphate 5-kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol diphosphate tetrakisphosphate kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (22)

Processvia Protein(s)Taxonomy
extracellular spaceInterferon betaHomo sapiens (human)
extracellular regionInterferon betaHomo sapiens (human)
Golgi membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
endoplasmic reticulumHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
Golgi apparatusHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
plasma membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
cell surfaceHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
ER to Golgi transport vesicle membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
secretory granule membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
phagocytic vesicle membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
early endosome membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
recycling endosome membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
extracellular exosomeHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
lumenal side of endoplasmic reticulum membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
MHC class I protein complexHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
extracellular spaceHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
external side of plasma membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
plasma membraneGlutamate receptor 2Rattus norvegicus (Norway rat)
fibrillar centerInositol hexakisphosphate kinase 1Homo sapiens (human)
nucleoplasmInositol hexakisphosphate kinase 1Homo sapiens (human)
cytosolInositol hexakisphosphate kinase 1Homo sapiens (human)
nucleusInositol hexakisphosphate kinase 1Homo sapiens (human)
cytoplasmInositol hexakisphosphate kinase 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (34)

Assay IDTitleYearJournalArticle
AID1347099qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID1508628Confirmatory qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347424RapidFire Mass Spectrometry qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347098qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347407qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Pharmaceutical Collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347103qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347096qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347107qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347097qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1508627Counterscreen qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: GLuc-NoTag assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347089qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1347105qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347091qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347104qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347108qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347092qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347100qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347095qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1508629Cell Viability qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347425Rhodamine-PBP qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347106qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1347101qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347102qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347094qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347093qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347090qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (373)

TimeframeStudies, This Drug (%)All Drugs %
pre-19908 (2.14)18.7374
1990's41 (10.99)18.2507
2000's237 (63.54)29.6817
2010's73 (19.57)24.3611
2020's14 (3.75)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials52 (12.75%)5.53%
Reviews39 (9.56%)6.00%
Case Studies53 (12.99%)4.05%
Observational0 (0.00%)0.25%
Other264 (64.71%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceDescriptionRelationhip StrengthStudiesTrialsClassesRoles
c.i. 42510[no description available]medium40050
fluorescein-5-isothiocyanate[no description available]medium10fluorescein isothiocyanate
technetium tc 99m sulfur colloid[no description available]medium1169
indocyanine green[no description available]medium1741,1-diunsubstituted alkanesulfonate;
benzoindole;
cyanine dye
methylene blue[no description available]medium326organic chloride saltacid-base indicator;
antidepressant;
antimalarial;
antimicrobial agent;
antioxidant;
cardioprotective agent;
EC 1.4.3.4 (monoamine oxidase) inhibitor;
EC 3.1.1.8 (cholinesterase) inhibitor;
EC 4.6.1.2 (guanylate cyclase) inhibitor;
fluorochrome;
histological dye;
neuroprotective agent;
physical tracer
sulfan blue[no description available]medium222organic molecular entity
technetium[no description available]medium131manganese group element atom
technetium 99m[no description available]medium11technetium atom
technetium tc 99m pentetate[no description available]medium21
mannans[no description available]medium21
rhenium[no description available]medium40manganese group element atom
chlorine[no description available]medium10halide anion;
monoatomic chlorine		cofactor;
Escherichia coli metabolite;
human metabolite
sodium pertechnetate tc 99m[no description available]medium11
fluorescein[no description available]medium502-benzofurans;
gamma-lactone;
organic heteropentacyclic compound;
oxaspiro compound;
polyphenol;
xanthene dye		fluorescent dye;
radioopaque medium
fluorouracil[no description available]medium10nucleobase analogue;
organofluorine compound		antimetabolite;
antineoplastic agent;
environmental contaminant;
immunosuppressive agent;
radiosensitizing agent;
xenobiotic
epirubicin[no description available]medium10aminoglycoside;
anthracycline antibiotic;
anthracycline;
deoxy hexoside;
monosaccharide derivative;
p-quinones;
primary alpha-hydroxy ketone;
tertiary alpha-hydroxy ketone		antimicrobial agent;
antineoplastic agent;
EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor
fluorodeoxyglucose f18[no description available]medium102-deoxy-2-((18)F)fluoro-D-glucose;
2-deoxy-2-fluoro-aldehydo-D-glucose
sulfur[no description available]medium10chalcogen;
nonmetal atom		macronutrient
hematoxylin[no description available]medium40organic heterotetracyclic compound;
oxacycle;
polyphenol;
tertiary alcohol		histological dye;
plant metabolite
eosine yellowish-(ys)[no description available]medium30organic sodium salt;
organobromine compound		fluorochrome;
histological dye
perfluorobutane[no description available]medium10fluoroalkane;
fluorocarbon;
gas molecular entity		ultrasound contrast agent
diphenhydramine[no description available]medium10ether;
tertiary amino compound		anti-allergic agent;
antidyskinesia agent;
antiemetic;
antiparkinson drug;
antipruritic drug;
antitussive;
H1-receptor antagonist;
local anaesthetic;
muscarinic antagonist;
oneirogen;
sedative
gadolinium[no description available]medium20f-block element atom;
lanthanoid atom
bromochloroacetic acid[no description available]medium1032-bromocarboxylic acid;
monocarboxylic acid;
organochlorine compound
docetaxel anhydrous[no description available]medium11secondary alpha-hydroxy ketone;
tetracyclic diterpenoid		antimalarial;
antineoplastic agent;
photosensitizing agent
formaldehyde[no description available]medium11aldehyde;
one-carbon compound		allergen;
carcinogenic agent;
disinfectant;
EC 3.5.1.4 (amidase) inhibitor;
environmental contaminant;
Escherichia coli metabolite;
mouse metabolite;
Saccharomyces cerevisiae metabolite
trypan blue[no description available]medium10
malachite green[no description available]medium10organic chloride saltantibacterial agent;
antifungal drug;
carcinogenic agent;
environmental contaminant;
fluorochrome;
histological dye;
teratogenic agent
gentian violet[no description available]medium10organic chloride saltanthelminthic drug;
antibacterial agent;
antifungal agent;
antiseptic drug;
histological dye
michler's ketone[no description available]medium10benzophenones
tolonium chloride[no description available]medium10
erythrosine[no description available]medium10
ConditionIndicatedRelationship StrengthStudiesTrials
Acinar Carcinoma0low10
Acinar Cell Adenocarcinoma0low10
Acinic Cell Adenocarcinoma0low10
Acinic Cell Carcinoma0low10
Acinic Cell Tumor0low10
Adenocarcinoma0medium213
Adenocarcinoma Of Kidney0low10
Adenocarcinoma, Basal Cell0medium213
Adenocarcinoma, Granular Cell0medium213
Adenocarcinoma, Mucinous0low10
Adenocarcinoma, Oxyphilic0medium213
Adenocarcinoma, Renal0low10
Adenocarcinoma, Renal Cell0low10
Adenocarcinoma, Sebaceous0low10
Adenocarcinoma, Tubular0medium213
Adenoma0medium11
Adenoma, Basal Cell0medium11
Adenoma, Follicular0medium11
Adenoma, Malignant0medium213
Adenoma, Microcystic0medium11
Adenoma, Monomorphic0medium11
Adenoma, Oxyphilic0low10
Adenoma, Papillary0medium11
Adenoma, Trabecular0medium11
Adenoma, Villous0low10
Allergic Reaction0low20
Allergy0low20
Allergy, Drug0medium101
Anal Cancer0low20
Anal Neoplasms0low20
Anaphylactic Reaction0medium291
Anaphylactoid Reaction0medium291
Anaphylactoid Shock0medium291
Anaphylaxis0medium291
Anesthesia0low10
Angioedema0low10
Angioneurotic Edema0low10
Anoxemia0low10
Anoxia0low10
Anus Neoplasms0low20
Argentaffinoma0low20
Ascites, Chylous0low10
Atheroembolism0low10
Atopic Hypersensitivity0low10
Atypical Ductal Hyperplasia0medium101
Atypical Endometrial Hyperplasia0low10
Auricular Cancer0low10
Auricular Neoplasms0low10
Barrett Epithelium0low10
Barrett Esophagus0low10
Barrett Metaplasia0low10
Barrett Syndrome0low10
Barrett's Esophagus0low10
Barrett's Syndrome0low10
Benign Neoplasms0low10
Blood Pressure, Low0medium41
Breast Cancer0medium14419
Breast Cancer Lymphedema0low10
Breast Cancer Related Lymphedema0low10
Breast Cancer Treatment-Related Lymphedema0low10
Breast Cancer-Related Arm Lymphedema0low10
Breast Cancer, Male0low30
Breast Carcinoma0medium14419
Breast Carcinoma, Male0low30
Breast Neoplasms, Male0low30
Breast Tumors0medium14419
Breast Tumors, Male0low30
Cadaver0low20
Cancer0low10
Cancer of Anus0low20
Cancer of Breast0medium14419
Cancer of Cervix0medium143
Cancer of Colon0medium238
Cancer of Digestive System0low10
Cancer of Ear0low10
Cancer of Ear Auricle0low10
Cancer of Endometrium0medium112
Cancer of Esophagus0low20
Cancer of Gastrointestinal Tract0medium41
Cancer of Head0low100
Cancer of Head and Neck0low100
Cancer of ILEUM0low10
Cancer of Kidney0low10
Cancer of Liver0low20
Cancer of Lung0medium71
Cancer of Mouth0low10
Cancer of Neck0low100
Cancer of Pelvis0low10
Cancer of Penis0low30
Cancer of Rectum0medium52
Cancer of Sigmoid0medium21
Cancer of Skin0medium444
Cancer of Stomach0medium103
Cancer of the Anus0low20
Cancer of the Breast0medium14419
Cancer of the Cervix0medium143
Cancer of the Colon0medium238
Cancer of the Digestive System0low10
Cancer of the Ear0low10
Cancer of the Endometrium0medium112
Cancer of the Esophagus0low20
Cancer of the Gastrointestinal Tract0medium41
Cancer of the Head0low100
Cancer of the Head and Neck0low100
Cancer of the ILEUM0low10
Cancer of the Kidney0low10
Cancer of the Liver0low20
Cancer of the Lung0medium71
Cancer of the Mouth0low10
Cancer of the Neck0low100
Cancer of the Pelvis0low10
Cancer of the Penis0low30
Cancer of the Rectum0medium52
Cancer of the Sigmoid0medium21
Cancer of the Skin0medium444
Cancer of the Stomach0medium103
Cancer of the Thyroid0medium41
Cancer of the Tongue0low10
Cancer of the Uterine Cervix0medium143
Cancer of the Uterus0medium51
Cancer of the Vulva0medium122
Cancer of Thyroid0medium41
Cancer of Tongue0low10
Cancer of Uterus0medium51
Cancer of Vulva0medium122
Cancer, Hepatocellular0low20
Cancer, Ileal0low10
Carcinoid0low20
Carcinoid Tumor0low20
Carcinoid, Goblet Cell0low20
Carcinoma0medium62
Carcinoma in Situ0medium21
Carcinoma of Endometrium0medium112
Carcinoma, Acinar Cell0low10
Carcinoma, Adenosquamous0low10
Carcinoma, Anaplastic0medium62
Carcinoma, Colloid0low10
Carcinoma, Cribriform0medium213
Carcinoma, Ductal0low10
Carcinoma, Ductal, Breast0medium122
Carcinoma, Epidermoid0low200
Carcinoma, Granular Cell0medium213
Carcinoma, Hypernephroid0low10
Carcinoma, Infiltrating Duct0medium122
Carcinoma, Intraductal0medium101
Carcinoma, Intraductal, Noninfiltrating0medium101
Carcinoma, Intraepithelial0medium21
Carcinoma, Invasive Ductal, Breast0medium122
Carcinoma, Lobular0medium81
Carcinoma, Mammary Ductal0medium122
Carcinoma, Merkel Cell0low50
Carcinoma, Mucinous0low10
Carcinoma, Non-Small Cell Lung0medium61
Carcinoma, Non-Small-Cell Lung0medium61
Carcinoma, Oat Cell0low10
Carcinoma, Papillary0low20
Carcinoma, Planocellular0low200
Carcinoma, Preinvasive0medium21
Carcinoma, Renal Cell0low10
Carcinoma, Small Cell0low10
Carcinoma, Spindle-Cell0medium62
Carcinoma, Squamous0low200
Carcinoma, Squamous Cell0low200
Carcinoma, Tubular0medium213
Carcinoma, Undifferentiated0medium62
Carcinomatosis0medium62
Carcinosarcoma0low10
Cellulitis0low10
Cervical Cancer0medium143
Cervical Neoplasms0medium143
Cervix Cancer0medium143
Cervix Neoplasms0medium143
Cholesterol Embolism0low10
Chromophil Renal Cell Carcinoma0low10
Chromophobe Renal Cell Carcinoma0low10
Chyloperitoneum0low10
Chylothorax0low10
Chylous Ascites0low10
Chylous Peritonitis0low10
Clear Cell Renal Carcinoma0low10
Clear Cell Renal Cell Carcinoma0low10
Collecting Duct Carcinoma0low10
Collecting Duct Carcinoma (Kidney)0low10
Collecting Duct Carcinoma of the Kidney0low10
Colon Cancer0medium238
Colon Neoplasms0medium238
Colonic Cancer0medium238
Colonic Neoplasms0medium238
Colorectal Cancer0medium161
Colorectal Carcinoma0medium161
Colorectal Neoplasms0medium161
Colorectal Tumors0medium161
Complex Endometrial Hyperplasia0low10
Complication, Intraoperative0low50
Complication, Peroperative0low50
Complication, Postoperative0medium141
Congenital Familial Lymphedema0low70
Congenital Hereditary Lymphedema0low70
Congenital Zika Syndrome0low10
Congenital Zika Virus Infection0low10
Conjunctival Neoplasms0low30
Corpse0low20
Cutaneous Fistula0low10
Cyanosis0low10
Cyst, Lymphatic0low60
DCIS0medium101
Deficiency, Oxygen0low10
Dermatitis Medicamentosa0low40
Dermatitis, Adverse Drug Reaction0low40
Digestive System Cancer0low10
Digestive System Neoplasms0low10
Disease Models, Animal0low30
Drug Allergy0medium101
Drug Eruptions0low40
Drug Hypersensitivity0medium101
Ductal Carcinoma0low10
Ductal Carcinoma In Situ0medium101
Dysesthesia0medium11
Dysplastic Nevus Syndrome, Hereditary0low20
Ear Cancer0low10
Ear Neoplasms0low10
Early Onset Lymphedema0low70
Ecchymosis0low10
Embolism, Cholesterol0low10
Endometrial Cancer0medium112
Endometrial Carcinoma0medium112
Endometrial Hyperplasia0low10
Endometrial Neoplasms0medium112
Endometrium Cancer0medium112
Epithelial Neoplasms, Malignant0medium62
Epithelial Tumors, Malignant0medium62
Epithelioma0medium62
Esophageal Cancer0low20
Esophageal Neoplasms0low20
Esophagus Cancer0low20
Esophagus Neoplasm0low20
Esophagus, Barrett0low10
External Fistula0low10
Extra-Mammary Paget Disease0low10
Extra-Mammary Paget's Disease0low10
Extramammary Paget Disease0low10
Extramammary Paget's Disease0low10
Eye Hemorrhage0low10
Eye Injuries0low10
Eyelid Diseases0low10
Eyelid Neoplasms0low10
Factitious Disorders0low10
Familial Atypical Mole-Malignant Melanoma Syndrome0low20
Famm0low20
Fat Necrosis0low10
Female Genital Neoplasms0low20
Fever, Zika0low10
Formication0medium11
Gangrene0low10
Ganser Syndrome0low10
Gastric Cancer0medium103
Gastric Cancer, Familial Diffuse0medium103
Gastric Neoplasms0medium103
Gastrointestinal Cancer0medium41
Gastrointestinal Neoplasms0medium41
Genital Neoplasms, Female0low20
Grawitz Tumor0low10
Gynecologic Neoplasms0low20
Head and Neck Cancer0low100
Head and Neck Neoplasm0low100
Head and Neck Neoplasms0low100
Head Cancer0low100
Head Neoplasm0low100
Head Neoplasms0low100
Head, Neck Neoplasms0low100
Hematoma0medium11
Hemophthalmos0low10
Hemorrhage, Eye0low10
Hepatic Cancer0low20
Hepatic Neoplasms0low20
Hepatocellular Cancer0low20
Hereditary Lymphedema0low70
Hereditary Lymphedema 10low70
Hereditary Lymphedema Type I0low70
Hives0low60
Huerthle Cell Tumor0low10
Human Mammary Carcinoma0medium14419
Hurthle Cell Tumor0low10
Hypernephroma0low10
Hypersensitivity0low20
Hypersensitivity, Atopic0low10
Hypersensitivity, Drug0medium101
Hypersensitivity, Immediate0low10
Hypersensitivity, Type I0low10
Hypotension0medium41
Hypotension, Vascular0medium41
Hypoxemia0low10
Hypoxia0low10
IgE-Mediated Hypersensitivity0low10
Ileal Cancer0low10
Ileal Neoplasms0low10
Infection, Postoperative Wound0medium11
Infection, Surgical Wound0medium11
Inflammation0low10
Inflammatory Breast Cancer0medium11
Inflammatory Breast Cancer (IBC)0medium11
Inflammatory Breast Carcinoma0medium11
Inflammatory Breast Neoplasms0medium11
Injuries, Eye0low10
Injuries, Surgical0low50
Innate Inflammatory Response0low10
Intraductal Carcinoma, Noninfiltrating0medium101
Intraepithelial Neoplasms0medium21
Intraoperative Complications0low50
Invasive Ductal Carcinoma, Breast0medium122
Invasiveness, Neoplasm0medium41
Kidney Cancer0low10
Kidney Neoplasms0low10
Liver Cancer0low20
Liver Neoplasms0low20
Local Neoplasm Recurrence0medium92
Local Neoplasm Recurrences0medium92
Locoregional Neoplasm Recurrence0medium92
Low Blood Pressure0medium41
Lung Cancer0medium71
Lung Neoplasms0medium71
Lymph Node Metastasis0medium18532
Lymphatic Abnormalities0low10
Lymphatic Cyst0low60
Lymphatic Diseases0low40
Lymphatic Metastasis0medium18532
Lymphatism0low40
Lymphedema0low70
Lymphedema, Early-Onset0low70
Lymphedema, Hereditary, Ia0low70
Lymphocele0low60
Lymphocoele0low60
Maculopapular Drug Eruption0low40
Maculopapular Exanthem0low40
Male Breast Cancer0low30
Male Breast Neoplasms0low30
Malignancy0low10
Malignant Epithelial Neoplasms0medium62
Malignant Melanoma0medium554
Malignant Neoplasm of Breast0medium14419
Malignant Neoplasms0low10
Malignant Tumor of Breast0medium14419
Mammary Cancer0medium14419
Mammary Carcinoma, Human0medium14419
Mammary Ductal Carcinoma0medium122
Mammary Neoplasm, Human0medium14419
Mammary Neoplasms, Human0medium14419
Melanoma0medium554
Melanoma, Cutaneous Malignant0low20
Melanoma, Familial0low20
Merkel Cell Cancer0low50
Merkel Cell Carcinoma0low50
Merkel Cell Tumor0low50
Merkle Tumors0low50
Metastase0medium21
Metastases, Neoplasm0medium21
Metastasis0medium21
Metastasis, Neoplasm0medium21
Methemoglobinemia0low20
Micrometastases, Neoplasm0medium42
Micrometastasis0medium42
Micrometastasis, Neoplasm0medium42
Milroy Disease0low70
Milroy's Disease0low70
Morbilliform Drug Reaction0low40
Morbilliform Exanthem0low40
Mouth Cancer0low10
Mouth Neoplasms0low10
Neck Cancer0low100
Neck Neoplasm0low100
Neck Neoplasms0low100
Neoplasia0low10
Neoplasm0low10
Neoplasm Invasion0medium41
Neoplasm Invasiveness0medium41
Neoplasm Metastases0medium21
Neoplasm Metastasis0medium21
Neoplasm Micrometastases0medium42
Neoplasm Micrometastasis0medium42
Neoplasm Recurrence, Local0medium92
Neoplasm Recurrence, Locoregional0medium92
Neoplasm Recurrences, Local0medium92
Neoplasms0low10
Neoplasms of Ear Auricle0low10
Neoplasms of Pelvis0low10
Neoplasms, Anal0low20
Neoplasms, Anus0low20
Neoplasms, Auricular0low10
Neoplasms, Benign0low10
Neoplasms, Breast0medium14419
Neoplasms, Breast, Male0low30
Neoplasms, Cervical0medium143
Neoplasms, Cervix0medium143
Neoplasms, Colonic0medium238
Neoplasms, Colorectal0medium161
Neoplasms, Digestive System0low10
Neoplasms, Ear0low10
Neoplasms, Endometrial0medium112
Neoplasms, Esophageal0low20
Neoplasms, Female Genital0low20
Neoplasms, Gastric0medium103
Neoplasms, Gastrointestinal0medium41
Neoplasms, Gynecologic0low20
Neoplasms, Head0low100
Neoplasms, Head and Neck0low100
Neoplasms, Hepatic0low20
Neoplasms, Intraepithelial0medium21
Neoplasms, Kidney0low10
Neoplasms, Liver0low20
Neoplasms, Lung0medium71
Neoplasms, Male Breast0low30
Neoplasms, Malignant Epithelial0medium62
Neoplasms, Mouth0low10
Neoplasms, Neck0low100
Neoplasms, Oral0low10
Neoplasms, Penile0low30
Neoplasms, Penis0low30
Neoplasms, Pulmonary0medium71
Neoplasms, Rectal0medium52
Neoplasms, Sebaceous Gland0low10
Neoplasms, Sigmoid0medium21
Neoplasms, Skin0medium444
Neoplasms, Stomach0medium103
Neoplasms, Thyroid0medium41
Neoplasms, Tongue0low10
Neoplasms, Upper Aerodigestive Tract0low100
Neoplasms, Uterine0medium51
Neoplasms, Uterus0medium51
Neoplasms, Vulvar0medium122
Nephroid Carcinoma0low10
Non-Small Cell Lung Cancer0medium61
Non-Small Cell Lung Carcinoma0medium61
Non-Small-Cell Lung Carcinoma0medium61
Nonne-Milroy Disease0low70
Nonne-Milroy Lymphedema0low70
Nonne-Milroy-Meige Disease0low70
Nonsmall Cell Lung Cancer0medium61
Oat Cell Carcinoma0low10
Obesity0low10
Oncocytoma0low10
Oral Cancer0low10
Oral Neoplasms0low10
Oxygen Deficiency0low10
Paget Disease Extramammary0low10
Paget Disease, Extra-Mammary0low10
Paget Disease, Extramammary0low10
Paget's Disease, Extra-Mammary0low10
Paget's Disease, Extramammary0low10
Papillary Renal Cell Carcinoma0low10
Paresthesia0medium11
Paresthesia, Distal0medium11
Paresthesia, Painful0medium11
Pelvic Cancer0low10
Pelvic Neoplasms0low10
Pelvis Cancer0low10
Pelvis Neoplasms0low10
Penile Cancer0low30
Penile Neoplasms0low30
Penis Cancer0low30
Penis Neoplasms0low30
Peritonitis, Chylous0low10
Peroperative Complications0low50
Phlegmon0low10
Post-mastectomy Lymphedema0low10
Postmastectomy Lymphedema0low10
Postoperative Complications0medium141
Postoperative Wound Infection0medium11
Primary Congenital Lymphedema0low70
Pseudodementia0low10
Pseudopsychosis0low10
Pulmonary Cancer0medium71
Pulmonary Neoplasms0medium71
Quincke's Edema0low10
Recrudescence0low30
Rectal Cancer0medium52
Rectal Neoplasms0medium52
Rectal Tumors0medium52
Rectum Cancer0medium52
Rectum Neoplasms0medium52
Recurrence0low30
Recurrence, Local Neoplasm0medium92
Recurrence, Locoregional Neoplasm0medium92
Recurrences, Local Neoplasm0medium92
Relapse0low30
Renal Cancer0low10
Renal Carcinoma0low10
Renal Cell Cancer0low10
Renal Cell Carcinoma0low10
Renal Cell Carcinoma, Papillary0low10
Renal Collecting Duct Carcinoma0low10
Renal Neoplasms0low10
Rhabdomyosarcoma0low10
Sarcoma0low20
Sarcoma, Epithelioid0low20
Sarcoma, Soft Tissue0low20
Sarcoma, Spindle Cell0low20
Sarcomatoid Renal Cell Carcinoma0low10
Scrotal Hydrocele0medium72
Sebaceous Gland Neoplasms0low10
Sensitivity and Specificity0medium569
Seroma0medium11
Serous Acinar Adenoma0low10
Shock, Anaphylactic0medium291
Sigmoid Cancer0medium21
Sigmoid Colon Cancer0medium21
Sigmoid Colon Neoplasms0medium21
Sigmoid Neoplasms0medium21
Sigmoidal Cancer0medium21
Simple Endometrial Hyperplasia0low10
Skin Cancer0medium444
Skin Fistula0low10
Skin Neoplasms0medium444
Small Cell Carcinoma0low10
Soft Tissue Neoplasms0low10
Squamous Cell Carcinoma0low200
Status Lymphaticus0low40
Steatonecrosis0low10
Stomach Cancer0medium103
Stomach Neoplasms0medium103
Surgical Injuries0low50
Surgical Site Infection0medium11
Surgical Wound Infection0medium11
Tachyarrhythmia0low10
Tachycardia0low10
Testicular Hydrocele0medium72
Thoracic Neoplasms0low10
Thyroid Adenoma0medium41
Thyroid Cancer0medium41
Thyroid Carcinoma0medium41
Thyroid Diseases0medium11
Thyroid Neoplasms0medium41
Tongue Cancer0low10
Tongue Neoplasms0low10
Tumors0low10
Tumors, Breast0medium14419
Tumors, Breast, Male0low30
Type I Hypersensitivity0low10
UADT Neoplasm0low100
UADT Neoplasms0low100
Upper Aerodigestive Tract Neoplasm0low100
Upper Aerodigestive Tract Neoplasms0low100
Urticaria0low60
Urticaria, Giant0low10
Uterine Cancer0medium51
Uterine Cervical Cancer0medium143
Uterine Cervical Neoplasms0medium143
Uterine Neoplasms0medium51
Uterus Cancer0medium51
Uterus Neoplasms0medium51
Vaginal Hydrocele0medium72
Varicocele0medium83
Vascular Hypotension0medium41
Vulva Cancer0medium122
Vulva Neoplasms0medium122
Vulvar Cancer0medium122
Vulvar Neoplasms0medium122
Wound Infection, Postoperative0medium11
Wound Infection, Surgical0medium11
Zika Fever0low10
Zika Virus Disease0low10
Zika Virus Infection0low10
ZikV Infection0low10

Research Highlights

Safety/Toxicity (4)

ArticleYear
Inflammatory cutaneous adverse effects of methylene blue dye injection for lymphatic mapping/sentinel lymphadenectomy.
Journal of surgical oncology, May-01, Volume: 99, Issue: 6		2009
Safety and efficacy of intratesticular injection of vital dyes for lymphatic preservation during varicocelectomy.
The Journal of urology, Volume: 178, Issue: 3 Pt 1		2007
Adverse events associated with the intraoperative injection of isosulfan blue.
Journal of clinical anesthesia, Volume: 16, Issue: 5		2004
Blue urticaria: a previously unreported adverse event associated with isosulfan blue.
Archives of surgery (Chicago, Ill. : 1960), Volume: 136, Issue: 12		2001
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Pharmacokinetics (2)

ArticleYear
Breast cancer sentinel lymph node identification rates: the influence of radiocolloid mapping, case volume, and the place of the procedure.
Annals of surgical oncology, Volume: 14, Issue: 5		2007
A prospective analysis of the effect of blue-dye volume on sentinel lymph node mapping success and incidence of allergic reaction in patients with breast cancer.
Annals of surgical oncology, Volume: 11, Issue: 5		2004
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioavailability (1)

ArticleYear
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
The Journal of biological chemistry, 11-15, Volume: 294, Issue: 46		2019
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]